{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000089","form_type":"8-K/A","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.258757+00:00","generated_at":"2026-06-08T05:57:00.469809+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ligand Q3 adj EPS $1.02 beats, raises 2023 guidance; restates prior net loss per share to ($0.59)","bullets":["Q3 total revenue $32.9M (down from $59.2M YoY, no COVID-19 sales); adjusted EPS $1.02 vs $0.60 YoY.","Raised 2023 revenue guidance to $126-129M (from $124-126M) and adjusted EPS to $5.25-5.40 (from $5.10-5.25).","8-K/A correction: $3.2M derivative asset from Pelican divestiture changed sale from ($1.1M) loss to $2.1M gain; net loss per share improved to ($0.59) from ($0.74).","Invested >$75M in Q3/Q4 in Tolerance, Ovid, Novan, Primrose; acquired 13% royalty interest in soticlestat (up to $86M milestones).","Cash and short-term investments $190.5M at Sep 30, 2023; new $75M revolving credit facility with Citibank."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000089","json":"https://secwatch.observer/filing/0000886163-23-000089.json","markdown":"https://secwatch.observer/filing/0000886163-23-000089.md","text":"https://secwatch.observer/filing/0000886163-23-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/0000886163-23-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/lgnd-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:57:00.469809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ea80b925f667bc0359594ecaa2938403d85bc61","claim":"LIGAND PHARMACEUTICALS INC reported three and nine months ended September 30, 2023 results: revenue $32.9 million, net income $10.3 million net loss, EPS $0.59 per share loss. Guidance raised.","evidence_excerpt":"at our upcoming Investor and Analyst Day scheduled for December 12th in New York City.” Third Quarter 2023 Financial Results Total revenues for the third quarter of 2023 were $32.9 million. Revenues for the same period in 2022 excluding sales related to COVID-19 were $26.9 million. Total revenues for the third quarter of 2022 including COVID-19 related sales were","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000089/0000886163-23-000089-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$32.9 million"},{"label":"Net income","value":"$10.3 million net loss"},{"label":"EPS","value":"$0.59 per share loss"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}